Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-243-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Skin sensitization (OECD 406): not sensitizing
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Justification for type of information:
- Refer to the Category Approach Justification document provided in IUCLID6 Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Species:
- mouse
- No. of animals per dose:
- 3
- Parameter:
- SI
- Value:
- 0.73
- Test group / Remarks:
- Daily topical application of 25 µl of a 5% solution.
- Parameter:
- SI
- Value:
- 1.61
- Test group / Remarks:
- Daily topical application of 25 µl of a 10% solution.
- Parameter:
- SI
- Value:
- 1.13
- Test group / Remarks:
- Daily topical application of 25 µl of a 25% solution.
- Parameter:
- SI
- Value:
- 1.58
- Test group / Remarks:
- Intradermal injection of 50 µL of a 0.05% solution in saline; after 5 days daily topical application of 25 µL of a 5% solution.
- Parameter:
- SI
- Value:
- 1.93
- Test group / Remarks:
- Intradermal injection of 50 µL of a 0.5% solution in saline; after 5 days daily topical application of 25 µL of a 5% solution.
- Parameter:
- SI
- Value:
- 1.48
- Test group / Remarks:
- Intradermal injection of 50 µL of a 5% solution in saline; after 5 days daily topical application of 25 µL of a 5% solution.
- Interpretation of results:
- GHS criteria not met
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Justification for type of information:
- Refer to the Category Approach Justification document provided in IUCLID6 Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Vehicle:
- other: water
- Concentration:
- 12.5 µl of a 10, 50 or 100% solution
- No. of animals per dose:
- 5
- Parameter:
- SI
- Value:
- 1.25
- Test group / Remarks:
- 12.5 µL of a 10% solution
- Parameter:
- SI
- Value:
- 2.7
- Test group / Remarks:
- 12.5 µL of a 50% solution
- Parameter:
- SI
- Value:
- 3.1
- Test group / Remarks:
- 12.5 µL of a 100% solution
- Interpretation of results:
- GHS criteria not met
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment Adopted according to OECD SIDS or other official EU regulation procedures (public available peer reviewed source).
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- yes
- Remarks:
- e.g. limited data on test substance available, only 3 insead of 4 animals per group
- GLP compliance:
- not specified
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- No. of animals per dose:
- 3
- Parameter:
- SI
- Value:
- 0.73
- Test group / Remarks:
- Daily topical application of 25 µl of a 5% solution.
- Parameter:
- SI
- Value:
- 1.61
- Test group / Remarks:
- Daily topical application of 25 µl of a 10% solution.
- Parameter:
- SI
- Value:
- 1.13
- Test group / Remarks:
- Daily topical application of 25 µl of a 25% solution.
- Parameter:
- SI
- Value:
- 1.58
- Test group / Remarks:
- Intradermal injection of 50 µL of a 0.05% solution in saline; after 5 days daily topical application of 25 µL of a 5% solution.
- Parameter:
- SI
- Value:
- 1.93
- Test group / Remarks:
- Intradermal injection of 50 µL of a 0.5% solution in saline; after 5 days daily topical application of 25 µL of a 5% solution.
- Parameter:
- SI
- Value:
- 1.48
- Test group / Remarks:
- Intradermal injection of 50 µL of a 5% solution in saline; after 5 days daily topical application of 25 µL of a 5% solution.
- Interpretation of results:
- GHS criteria not met
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
- Justification for type of information:
- Refer to the Category Approach Justification document provided in IUCLID6 Section 13.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- yes
- Remarks:
- Only limited data on test item and methodology available
- Principles of method if other than guideline:
- Method: other
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Vehicle:
- other: water
- Concentration:
- 12.5 µl of a 10, 50 or 100% solution
- No. of animals per dose:
- 5
- Parameter:
- SI
- Value:
- 1.25
- Test group / Remarks:
- 12.5 µL of a 10% solution
- Parameter:
- SI
- Value:
- 2.7
- Test group / Remarks:
- 12.5 µL of a 50% solution
- Parameter:
- SI
- Value:
- 3.1
- Test group / Remarks:
- 12.5 µL of a 100% solution
- Interpretation of results:
- GHS criteria not met
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Referenceopen allclose all
Stimulation indices: a.) 0.73, 1.61 and 1.13; b.) 1.58, 1.93 or 1.48
The treatment had no significant effect on thymidine incorporation by
auricular lymph node cells when compared with naive and carrier controls:
stimulation index: 1.25, 2.7 or 3.1
naive control: 2.4
carrier control: 1
Stimulation indices: a.) 0.73, 1.61 and 1.13; b.) 1.58, 1.93 or 1.48
The treatment had no significant effect on thymidine incorporation by
auricular lymph node cells when compared with naive and carrier controls:
stimulation index: 1.25, 2.7 or 3.1
naive control: 2.4
carrier control: 1
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
There is no study regarding skin sensitisation with C9-12AS Na (CAS n.a.) available. Therefore this endpoint is covered by read across to structurally related alkyl sulfates (AS), i.e. C8AS Na (CAS 142-31-4) and C12AS Na (CAS 151-21-3). The possibility of a read-across to other alkyl sulfates in accordance with Regulation (EC) No 1907/2006 Annex XI 1.5. Grouping of substances and read-across approach was assessed. In Annex XI 1.5 it is given that a read-across approach is possible for substances, whose physicochemical, toxicological and ecotoxicological properties are likely to be similar or follow a regular pattern as a result of structural similarity. The AS reported within the AS category show structural similarity. The most important common structural feature of the category members is the presence of a predominantly linear aliphatic hydrocarbon chain with a polar sulfate group, neutralized with a counter ion. This structural feature confers the surfactant properties of the alkyl sulfates. The surfactant property of the members of the AS category in turn represent the predominant attribute in mediating effects on mammalian health. Therefore, the AS of the AS category have similar physico-chemical, environmental and toxicological properties, validating the read across approach within the category. The approach of grouping different AS for the evaluation of their effects on human health and the environment was also made by the OECD in the SIDS initial assessment profile [1] and by a voluntary industry programme carrying out Human and Environmental Risk Assessments (HERA [2]), further supporting the read across approach between structurally related AS.
One study assessed the skin sensitizing potential of C8AS Na (CAS 142-31-4, analytical purity 32%) in a Local Lymph Node Assay similar to OECD Guideline 429 (Anonymous, 1992). In this study 12.5 µL of a 10, 50 and 100% aqueous solution of the test substance were topically applied on 4 consecutive days to 5 female CBA mice per dose group. 21 h after the last treatment all animals received injections with radiolabelled thymidine. Animals were sacrificed 5 h thereafter and auricular lymph nodes were removed. Single cell suspensions were prepared, washed and precipitated. The total radio counts in these precipitates were subsequently quantified by liquid scintillation spectrometry. The stimulation index in the carrier control was 1. The stimulation indices for the naïve control and animals treated with 10, 50 and 100% of the test substance were 2.4, 1.25, 2.7 and 3.1, respectively. The treatment had no significant effect on thymidine incorporation and thus the test substance showed not sensitising potential.
The skin sensitizing potential of C12AS Na (CAS 151-21-3) was assessed in a local lymph node assay similar to OECD guideline 429 (Ikarashi, 1993) on 3 mice per dose and experiment. BALB/c mice were treated daily via topical application (25 µL) of 5, 10 and 25% aqueous solution of the test item on 3 consecutive days. In another experiment intradermal injections (50 µL) were performed with concentrations of 0.05, 0.5 or 5% in saline. Five days after intradermal injection, mice were challenged daily by dermal application of 25 µL of a 5% solution in vehicle (DMSO 50%) on the ears for 3 consecutive days. The day after the final exposure, changes in lymph node weight, total cell number in the draining lymph nodes and LNC proliferation for 24 h culture were assessed. The stimulation indices in the first experiment were 0.7, 1.6 and 1.1 at 5, 10 and 25%. After intradermal application of 0.05, 0.5 or 5% test item and subsequent dermal challenge with 5% test item the stimulation indices were 1.6, 1.9 and 1.5.
Results of the above mentioned study show that C8AS Na and C12AS Na is not skin sensitising. In addition, sodium lauryl sulphate ( C12AS Na) was used within the above mentioned study as known irritant to produce irritant effects. Likewise sodium lauryl sulphate is also recommended as an agent to induce local irritation in an OECD method to assess skin sensitising properties of chemicals (OECD guideline 406, Guinea Pig Maximisation Test). Therefore there is a lot of experience with sodium lauryl sulfate in sensitising studies and no evidence that it shows sensitising properties. Thus, skin sensitisation by members of the alkyl sulfates is generally unlikely.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
According to the classification criteria of Directive 67/548/EEC and Regulation (EC) No 1272/2008 the substance does not need to be classified for skin sensitization. No data is available for respiratory sensitization.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.